The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-14. Anything still debated is marked as such rather than presented as settled.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
The most common adverse effects of esketamine for depression (≥5% incidence) include dissociation, dizziness, sedation, nausea, vomiting, vertigo, numbness, anxiety, lethargy, increased blood pressure, and feelings of drunkenness. Long-term abuse of ketamine has been associated with bladder disease.
== Research == Guselkumab has undergone phase III clinical trials comparing it with adalimumab (Humira) and ustekinumab (Stelara). The safety and efficacy of guselkumab was compared to a placebo and to adalimumab in the "VOYAGE 1" and "VOYAGE 2" phase III clinical trials (ClinicalTrials.gov IDs: NCT02207231 and NCT02207244). Preliminary results indicated that a significantly higher proportion of patients taking guselkumab had better skin clearance compared to those taking the other treatments. At week 16, 73.3% of patients taking guselkumab achieved a PASI 90 (90% reduction in PASI score from baseline), vs 49.7% of those taking adalimumab; additionally, 91.2% of patients taking guselkumab achieved a PASI 75 (75% reduction in PASI score from baseline), vs 73.1% of those taking adalimumab. The phase III clinical trial "NAVIGATE" (ClinicalTrials.gov ID: NCT02203032) included only patients who had poor responses to treatment with ustekinumab. It showed that patients who switched to guselkumab from ustekinumab did better than those who remained on ustekinumab.
Copernicium is a synthetic chemical element; it has symbol Cn and atomic number 112. Its known isotopes are extremely radioactive, and have only been created in a laboratory. The most stable known isotope, copernicium-285, has a half-life of approximately 30 seconds. Copernicium was first created in February 1996 by the GSI Helmholtz Centre for Heavy Ion Research near Darmstadt, Germany. It was named after the astronomer Nicolaus Copernicus on his 537th anniversary. In the periodic table of the elements, copernicium is a d-block transactinide element and a group 12 element. During reactions with gold, it has been shown to be an extremely volatile element, so much so that it is possibly a gas or a volatile liquid at standard temperature and pressure. Copernicium is calculated to have several properties that differ from its lighter homologues in group 12, zinc, cadmium and mercury; due to relativistic effects, it may give up its 6d electrons instead of its 7s ones, and it may have more similarities to the noble gases such as radon rather than its group 12 homologues. Calculations indicate that copernicium may show the oxidation state +4, while mercury shows it in only one compound of disputed existence and zinc and cadmium do not show it at all. It has also been predicted to be more difficult to oxidize copernicium from its neutral state than the other group 12 elements. Predictions vary on whether solid copernicium would be a metal, semiconductor, or insulator. Copernicium is one of the heaviest elements whose chemical properties have been experimentally investigated.
== Partnerships == On 5 September 2012, Nokia announced a deal with the chain to offer wireless charging facilities in its cafés. On May 28, 2013, Hilton Worldwide announced they had signed an exclusive agreement for Coffee Bean to provide in-room coffee and tea for all Hilton hotels in North America, South America, and Central America. Green Mountain Coffee Roasters announced on May 29, 2013, that they had partnered with Coffee Bean to create a K-Cup for Keurig single-cup brewing systems, available in the US as of 2014. On August 24, 2015, the firm announced they had signed an exclusive area development agreement with South Korean retail conglomerate E-LAND to enter into the Chinese market. On July 21, 2020, the Coffee Bean & Tea Leaf entered into a partnership with fast casual chain Smashburger, and began incorporating Coffee Bean & Tea Leaf products into their menu.
Sources: en.wikipedia.org
This means that the application of DBNPA can circumvent the bacterial antibiotic resistance problem of FDA concern, making it a successful alternative to antibiotics. Then agricultural use of DDGS in feed would represent a safer practice because DBNPA would be degraded, would make the use of antibiotics oblivious and reduce antibiotic resistance in bacteria in bovine, swine, and poultry applications in the food chain.
Aspartame is an artificial, non-saccharide sweetener commonly used as a sugar substitute in foods and beverages. It is 200 times sweeter than sucrose, and is a methyl ester of the aspartic acid/phenylalanine dipeptide with brand names NutraSweet, Equal, and Canderel. Discovered in 1965, aspartame was approved by the US Food and Drug Administration (FDA) in 1974 and re-approved in 1981 after its initial approval was briefly revoked. Aspartame is one of the most studied food additives in the human food supply. Reviews by over 100 governmental regulatory bodies found the ingredient safe for consumption at the normal acceptable daily intake limit. A number of health organizations such as the American Heart Association, American Diabetes Association, and American Cancer Society are supportive of its use consistent with other approved low-calorie sweeteners.
1985 Franz Hillenkamp, Michael Karas and co-workers describe and coin the term matrix-assisted laser desorption ionization (MALDI). 1987 Koichi Tanaka uses the "ultra fine metal plus liquid matrix method" to ionize intact proteins. 1989 Wolfgang Paul receives the Nobel Prize in Physics "for the development of the ion trap technique". 1999 Alexander Makarov presents the Orbitrap mass spectrometer.
Sources: en.wikipedia.org
=== As an androgen === DHEA and other adrenal androgens such as androstenedione, although relatively weak androgens, are responsible for the androgenic effects of adrenarche, such as early pubic and axillary hair growth, adult-type body odor, increased oiliness of hair and skin, and mild acne. DHEA is potentiated locally via conversion into testosterone and dihydrotestosterone (DHT) in the skin and hair follicles. Women with complete androgen insensitivity syndrome (CAIS), who have a non-functional androgen receptor (AR) and are immune to the androgenic effects of DHEA and other androgens, have absent or only sparse/scanty pubic and axillary hair and body hair in general, demonstrating the role of DHEA and other androgens in body hair development at both adrenarche and pubarche.
=== Pharmacokinetics === Metandienone has high oral bioavailability. It has very low affinity for human serum sex hormone-binding globulin (SHBG), about 10% of that of testosterone and 2% of that of DHT. The drug is metabolized in the liver by 6β-hydroxylation, 3α- and 3β-oxidation, 5β-reduction, 17-epimerization, and conjugation among other reactions. Unlike methyltestosterone, owing to the presence of its C1(2) double bond, metandienone does not produce 5α-reduced metabolites. The elimination half-life of metandienone is about 3 to 6 hours. It is eliminated in the urine.
In the case of bleeding on probing, which is a diagnostic tool for dentists to routinely check the condition of the gums, the periodontal probe, when inserted gently into the gingival sulcus, is used to measure the depth of the periodontal pocket but upon contact with the sulcular epithelium, should not cause bleeding in individuals with good gingival health. This is due to the resiliency of the sulcular epithelium that has a healthy thickness with a strong underlying collagen architecture. Sites with greater inflammation tend to have more cells yet possess a weaker collagen architecture, making bleeding on probing more noticeable, which is a common finding in stage 2 (early) gingivitis. This highlights the importance of the sulcular epithelium as a physical barrier to protect the underlying connective tissue. When its surface is ulcerated and discontinuous, it allows bacteria to enter more easily. In fact, the total area where bacteria can come in contact with the affected gum tissue is estimated to be as large as the palm of an adult’s hand. Once in the established lesion stage of gingivitis, collagen depletion continues as more polymorphonuclear (PMN) cells seep into the gingival sulcus and infiltrate the spaces within the sulcular epithelium. Permeability of the gingival sulcus (sulcular epithelium & junctional epithelium) also increases with the progress of gingival inflammation.
== See also == RO5166017 – TAAR1 partial or full agonist RO5203648 – TAAR1 partial agonist RO5256390 – TAAR1 partial or full agonist RO5263397 – TAAR1 partial agonist EPPTB – TAAR1 antagonist/inverse agonist
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.